Stock TOVX THERIVA BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Delayed Nyse
Other stock markets
 17:53:41 17/05/2024 BST 		5-day change 1st Jan Change
0.3796 USD +1.48% Intraday chart for Theriva Biologics, Inc. +4.29% -11.74%
05-07 Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-23 Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery
CI
Synthetic Biologics, Inc. has Changed its Name to Theriva Biologics, Inc
CI
Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline
CI
Synthetic Biologics Names Frank Tufaro Chief Operating Officer
MT
Synthetic Biologics, Inc. Announces Management Transitions in Support of Strategic Transformation
CI
Synthetic Biologics, Inc. Announces Executive Changes
CI
Synthetic Biologics, Inc. Appoints Steven A. Shallcross as Chief Executive Officer and Director
CI
Synthetic Biologics, Inc. Announces Executive Changes, Effective December 2018
CI
Synthetic Biologics Announces Management Changes
CI
Synthetics Biologics, Inc. Appoints Dr. Sliman as Chief Medical Officer
CI
Isaac J. Bright Joins Synthetic Biologics as Vice President, Corporate Development
CI
Synthetic Biologics Appoints Deb Mathews as Vice President, Medical Affairs
CI
Synthetic Biologics Inc. Appoints Raymond Stapleton as Senior Vice President of Manufacturing
CI
Klaus Gottlieb Joins Synthetic Biologics Inc. as Vice President, Clinical & Regulatory Affairs, Effective June 22, 2015
CI
Maureen Early Joins Synthetic Biologics Inc. as Vice President, Commercial
CI
Synthetic Biologics Inc. Announces Management Changes
CI
Synthetic Biologics, Inc. Announces Appointments to Clinical Advisory Board
CI
Synthetic Biologics Inc. Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program
CI
Synthetic Biologics Appoints Mark Pimentel, M.D., Chairman of New Irritable Bowel Syndrome Clinical Advisory Board
CI
Synthetic Biologics Inc. Announces Resignation of Steve H. Kanzer, Founder, Board Member and Subsidiary CEO and President
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TOVX Stock
  4. News Theriva Biologics, Inc.
  5. Insiders